Pasteur Sanofi/Centocor
This article was originally published in The Gray Sheet
Executive Summary
Ink non-exclusive worldwide distribution pact in the cancer field. Under the terms of the deal, Pasteur Sanofi Diagnostics will distribute, in conjunction with its own Access automated instrument, five tumor markers developed by Centocor: CA 19-9, CA 125, CA 15-3, CA 72-4, and PSA. The markers add to the CEA and alpha-fetoprotein tumor markers previously developed by Daiichi Pure Chemicals, Pasteur Sanofi Diagnostics' partner and exclusive distributor in Japan. Sanofi began marketing the Access in mid- 1993. The analyzer is available with 15 assays worldwide and 13 in the U.S
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.